Prelude Therapeutics Inc (PRLD)

$4.09

-0.03

(-0.73%)

Market is closed - opens 7 PM, 22 May 2024

Insights on Prelude Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 55.9% return, outperforming this stock by 81.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 227.0% return, outperforming this stock by 316.4%

Performance

  • $4.03
    $4.26
    $4.09
    downward going graph

    1.47%

    Downside

    Day's Volatility :5.4%

    Upside

    3.99%

    downward going graph
  • $1.66
    $6.03
    $4.09
    downward going graph

    59.41%

    Downside

    52 Weeks Volatility :72.47%

    Upside

    32.17%

    downward going graph

Returns

PeriodPrelude Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
8.99%
0.4%
0.0%
6 Months
27.55%
12.5%
0.0%
1 Year
-24.68%
11.2%
0.0%
3 Years
-89.36%
17.4%
-20.1%

Highlights

Market Capitalization
219.7M
Book Value
$3.84
Earnings Per Share (EPS)
-1.86
Wall Street Target Price
4.75
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-38.59%
Return On Equity TTM
-65.04%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-136.2M
Diluted Eps TTM
-1.86
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.68
EPS Estimate Next Year
-1.42
EPS Estimate Current Quarter
-0.48
EPS Estimate Next Quarter
-0.49

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Prelude Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 16.14%

Current $4.09
Target $4.75

Technicals Summary

Sell

Neutral

Buy

Prelude Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prelude Therapeutics Inc
Prelude Therapeutics Inc
7.01%
27.55%
-24.68%
-89.36%
-84.27%
Moderna, Inc.
Moderna, Inc.
34.99%
82.8%
11.26%
-12.66%
521.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.68%
23.59%
31.37%
94.84%
218.53%
Novo Nordisk A/s
Novo Nordisk A/s
6.11%
29.32%
55.89%
226.96%
459.27%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.49%
25.68%
31.15%
108.91%
163.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prelude Therapeutics Inc
Prelude Therapeutics Inc
NA
NA
NA
-1.68
-0.65
-0.39
NA
3.84
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.98
28.98
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.48
45.48
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.91
28.91
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prelude Therapeutics Inc
Prelude Therapeutics Inc
Buy
$219.7M
-84.27%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$50.9B
521.19%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.2B
218.53%
28.98
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$587.5B
459.27%
45.48
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$114.9B
163.64%
28.91
39.46%

Institutional Holdings

  • Orbimed Advisors, LLC

    19.86%
  • Baker Bros Advisors LP

    18.43%
  • Boxer Capital LLC

    4.68%
  • BlackRock Inc

    1.99%
  • T. Rowe Price Associates, Inc.

    1.90%
  • Vanguard Group Inc

    1.83%

Corporate Announcements

  • Prelude Therapeutics Inc Earnings

    Prelude Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.

Organization
Prelude Therapeutics Inc
Employees
128
CEO
Dr. Krishna Vaddi D.V.M., Ph.D.
Industry
Health Technology

FAQs